P: Antiparasitic products, insecticides and repellents

ATC group P covers drugs against parasites: antimalarials and other antiprotozoals, anthelmintics against worms, and treatments for lice and scabies.
Updated

September 25, 2026

ATC group P holds drugs against parasites: antiprotozoals (P01), anthelmintics against worms (P02), and ectoparasiticides, insecticides and repellents (P03) [1]. Compared with viruses and bacteria, eukaryotic parasites have genomes and proteins that closely resemble those of their human hosts. Many anti-infective drugs act on host targets as well as on pathogen targets [2].

Table 1: ATC P level 2 codes
Description In plain terms Example drug
P01 Antiprotozoals kill single-celled parasites: malaria, amoebiasis, giardiasis Artemether/lumefantrine (P01BF01) / metronidazole (P01AB01)
P02 Anthelmintics deworming drugs against parasitic worms Albendazole (P02CA03) / praziquantel (P02BA01)
P03 Ectoparasiticides, incl. scabicides, insecticides and repellents kill skin parasites: scabies mites, lice; repellents Permethrin (P03AC04) / diethyltoluamide, i.e. DEET (P03BX01)

Dosing children

WHO treatment guidelines give children’s doses as weight bands, fixed dose steps by body weight. The bands differ between diseases, which complicates dosing a child treated for several diseases at once. A harmonized set of weight bands for tuberculosis, HIV, malaria and hepatitis C was judged feasible [3].

Infants are usually excluded from early dose-finding studies of antimalarials, so their doses are often extrapolated from older children or adults. Population PKPD modeling can support dose optimization from the sparse data that can be collected in infants [4]. For scaling clearance in children, allometric weight scaling with an exponent of 0.75 combined with a sigmoid maturation function has been proposed as a standard model, against which published models were compared [5].

References

[1]
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2026 2026.
[2]
Chan JD et al. Polypharmacology of anthelmintics at host and parasite ion channels. PLoS Pathogens 2026;22:e1013977. https://doi.org/10.1371/journal.ppat.1013977.
[3]
Waalewijn H et al. Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas. The Lancet Child & Adolescent Health 2025;9:274–82. https://doi.org/10.1016/S2352-4642(25)00025-2.
[4]
Banda CG, Tarning J, Barnes KI. Use of population pharmacokinetic-pharmacodynamic modelling to inform antimalarial dose optimization in infants. British Journal of Clinical Pharmacology 2025;91:968–80. https://doi.org/10.1111/bcp.16132.
[5]
Germovsek E, Barker CIS, Sharland M, Standing JF. Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful? Brit J Clinical Pharma 2017;83:777–90. https://doi.org/10.1111/bcp.13160.